These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 32111396)

  • 1. Pancreatic acinar cell carcinomas and mixed acinar-neuroendocrine carcinomas are more clinically aggressive than grade 1 pancreatic neuroendocrine tumours.
    Kim JY; Brosnan-Cashman JA; Kim J; An S; Lee KB; Kim H; Park DY; Jang KT; Oh YH; Hruban RH; Heaphy CM; Hong SM
    Pathology; 2020 Apr; 52(3):336-347. PubMed ID: 32111396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.
    Kim JY; Brosnan-Cashman JA; An S; Kim SJ; Song KB; Kim MS; Kim MJ; Hwang DW; Meeker AK; Yu E; Kim SC; Hruban RH; Heaphy CM; Hong SM
    Clin Cancer Res; 2017 Mar; 23(6):1598-1606. PubMed ID: 27663587
    [No Abstract]   [Full Text] [Related]  

  • 3. Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma.
    Stelow EB; Shaco-Levy R; Bao F; Garcia J; Klimstra DS
    Am J Surg Pathol; 2010 Apr; 34(4):510-8. PubMed ID: 20182344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbonic anhydrase 9 expression in well-differentiated pancreatic neuroendocrine neoplasms might be associated with aggressive behavior and poor survival.
    Kim JY; Lee SH; An S; Kim SJ; Sung YN; Song KB; Hwang DW; Kim SC; Hong SM
    Virchows Arch; 2018 May; 472(5):739-748. PubMed ID: 29666945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting recurrence in pancreatic neuroendocrine tumours: role of ARX and alternative lengthening of telomeres (ALT).
    Neyaz A; Crotty R; Rickelt S; Pankaj A; Stojanova M; Michelakos TP; Sekigami Y; Kontos F; Parrack PH; Patil DT; Heaphy CM; Ferrone CR; Deshpande V
    Histopathology; 2023 Oct; 83(4):546-558. PubMed ID: 37455385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic study of 62 acinar cell carcinomas of the pancreas: insights into the morphology and immunophenotype and search for prognostic markers.
    La Rosa S; Adsay V; Albarello L; Asioli S; Casnedi S; Franzi F; Marando A; Notohara K; Sessa F; Vanoli A; Zhang L; Capella C
    Am J Surg Pathol; 2012 Dec; 36(12):1782-95. PubMed ID: 23026929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
    Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
    Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.
    Hackeng WM; Brosens LAA; Kim JY; O'Sullivan R; Sung YN; Liu TC; Cao D; Heayn M; Brosnan-Cashman J; An S; Morsink FHM; Heidsma CM; Valk GD; Vriens MR; Nieveen van Dijkum E; Offerhaus GJA; Dreijerink KMA; Zeh H; Zureikat AH; Hogg M; Lee K; Geller D; Marsh JW; Paniccia A; Ongchin M; Pingpank JF; Bahary N; Aijazi M; Brand R; Chennat J; Das R; Fasanella KE; Khalid A; McGrath K; Sarkaria S; Singh H; Slivka A; Nalesnik M; Han X; Nikiforova MN; Lawlor RT; Mafficini A; Rusev B; Corbo V; Luchini C; Bersani S; Pea A; Cingarlini S; Landoni L; Salvia R; Milione M; Milella M; Scarpa A; Hong SM; Heaphy CM; Singhi AD
    Gut; 2022 May; 71(5):961-973. PubMed ID: 33849943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of a novel antibody in the pathological diagnosis of pancreatic acinar cell carcinoma.
    Yasumoto M; Hamabashiri M; Akiba J; Ogasawara S; Naito Y; Taira T; Nakayama M; Daicho A; Yamasaki F; Shimamatsu K; Ishida Y; Kaji R; Okabe Y; Nakashima O; Ohshima K; Nakashima M; Sata M; Yano H
    J Clin Pathol; 2012 Apr; 65(4):327-32. PubMed ID: 22228907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study.
    Kim H; An S; Lee K; Ahn S; Park DY; Kim JH; Kang DW; Kim MJ; Chang MS; Jung ES; Kim JM; Choi YJ; Jin SY; Chang HK; Cho MY; Kang YK; Kang M; Ahn S; Kim YW; Hong SM;
    Cancer Res Treat; 2020 Jan; 52(1):263-276. PubMed ID: 31319641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-MYC amplification and c-myc protein expression in pancreatic acinar cell carcinomas. New insights into the molecular signature of these rare cancers.
    La Rosa S; Bernasconi B; Vanoli A; Sciarra A; Notohara K; Albarello L; Casnedi S; Billo P; Zhang L; Tibiletti MG; Sessa F
    Virchows Arch; 2018 Oct; 473(4):435-441. PubMed ID: 29721608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Grading of well-differentiated pancreatic neuroendocrine tumors is improved by the inclusion of both Ki67 proliferative index and mitotic rate.
    McCall CM; Shi C; Cornish TC; Klimstra DS; Tang LH; Basturk O; Mun LJ; Ellison TA; Wolfgang CL; Choti MA; Schulick RD; Edil BH; Hruban RH
    Am J Surg Pathol; 2013 Nov; 37(11):1671-7. PubMed ID: 24121170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of nectin-3 expression as a marker of tumor aggressiveness in pancreatic neuroendocrine tumor.
    Hirabayashi K; Tajiri T; Bosch DE; Morimachi M; Miyaoka M; Inomoto C; Nakamura N; Yeh MM
    Pathol Int; 2020 Feb; 70(2):84-91. PubMed ID: 31855317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic acinar cell carcinoma.
    Ordóñez NG
    Adv Anat Pathol; 2001 May; 8(3):144-59. PubMed ID: 11345238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural History and Treatment Trends in Pancreatic Cancer Subtypes.
    Pokrzywa CJ; Abbott DE; Matkowskyj KA; Ronnekleiv-Kelly SM; Winslow ER; Weber SM; Fisher AV
    J Gastrointest Surg; 2019 Apr; 23(4):768-778. PubMed ID: 30706376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-Ductal Tumors of the Pancreas.
    Dhillon J
    Monogr Clin Cytol; 2020; 26():92-108. PubMed ID: 32987393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraductal and papillary variants of acinar cell carcinomas: a new addition to the challenging differential diagnosis of intraductal neoplasms.
    Basturk O; Zamboni G; Klimstra DS; Capelli P; Andea A; Kamel NS; Adsay NV
    Am J Surg Pathol; 2007 Mar; 31(3):363-70. PubMed ID: 17325477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TFE3 is a diagnostic marker for solid pseudopapillary neoplasms of the pancreas.
    Jiang Y; Xie J; Wang B; Mu Y; Liu P
    Hum Pathol; 2018 Nov; 81():166-175. PubMed ID: 30030118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastric mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) with pancreatic acinar differentiation: a case report.
    Fujita Y; Uesugi N; Sugimoto R; Eizuka M; Matsumoto T; Sugai T
    Diagn Pathol; 2019 May; 14(1):38. PubMed ID: 31077220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aggressive approach to acinar cell carcinoma of the pancreas: a single-institution experience and a literature review.
    Butturini G; Pisano M; Scarpa A; D'Onofrio M; Auriemma A; Bassi C
    Langenbecks Arch Surg; 2011 Mar; 396(3):363-9. PubMed ID: 20803029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.